NCT01408641

Topiramate for Alcohol Use in Posttraumatic Stress Disorder

A 14-week Randomized, Placebo-controlled Study of Topiramate for Alcohol Use Disorders in Veterans With Posttraumatic Stress Disorder

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: University of Maryland, Baltimore · Academic / Other
• Sex: Male
• Age: 21 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

Alcohol abuse and dependence (alcohol use disorders, AUDs) and posttraumatic stress disorder (PTSD) are both prevalent in Veterans. Treating AUDs in Veterans with PTSD may be more difficult than treating AUDs in the general population. The FDA-approved medication topiramate has been shown to improve drinking outcomes in people with AUDs. Topiramate has also improved symptoms in people with PTSD. This study is designed to investigate whether topiramate will improve drinking outcomes in Veterans with PTSD.

Conditions

• Alcohol Dependence
• Alcoholism
• Alcohol Abuse
• Alcohol Use Disorder
• PTSD
• Posttraumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	Topiramate	Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
DRUG	Placebo	Placebo capsules without topiramate

Timeline

• Start date: 2012-09-01
• Primary completion: 2013-07-01
• Completion: 2013-08-01
• First posted: 2011-08-03
• Last updated: 2022-03-03
• Results posted: 2018-05-24

Locations

1 site across 1 country: United States